Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1307 - Efficacy of regorafenib in metastatic colorectal cancer: a multi-institutional retrospective study


24 Nov 2018


Poster display - Cocktail


Tumour Site

Colon and Rectal Cancer


M. Shouki Bazarbashi


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


M..S. Bazarbashi1, M.A. Elshenawy2, M.S. Kandil3, M. Zahir4, A. Shaheen5, A. Gad6, O. Alshaer7, A.M. Alzahrani1, A. Eldali8, A. Aljubran1

Author affiliations

  • 1 Oncology, King Faisal Specialist Hospital and Research Center, 11211 - Riyadh/SA
  • 2 Oncology, Faculty of Medicine - Menoufia University, 32511 - Shebin El Kom/EG
  • 3 Oncology, Prince Sultan Military Medical city, 11159 - Riyadh/SA
  • 4 Oncology, King Faisal Specialist Hospital And Research Centre, 12713 - Riyadh/SA
  • 5 Oncology, King Fahad Specialist Hospital Dammam, Dammam/SA
  • 6 Clinical Oncology, Ain Shams University Hospital, 11435 - cairo/EG
  • 7 Medicine, Security Forces Hospital, 11585 - Riyadh/SA
  • 8 Biostatistics, Epidemiology And Scientific Computing, King Faisal Specialist Hospital and Research Center, 11211 - Riyadh/SA

Abstract 1307


Regorafenib is a multi-kinase inhibitor that was approved for treatment of refractory advanced colorectal cancer. It has been found in clinical trials to have modest benefit and a relatively significant toxicity. Our aim was to assess the efficacy of regorafenib in our local clinic practice.


Records of all confirmed colorectal cancer cases who were treated with regorafenib were reviewed. Clinical, pathological and molecular data were collected. Efficacy and factors of possible prognostic significance were analysed.


Seventy-eight patients with metastatic colorectal cancer were treated with regorafenib from February 2014 to February 2016 in 4 different institutions. Median age: 50.5 years. Male: 40 (51.3%). KRAS mutant: 41 (52%). Right colonic primary: 18 (23%). Fifty-two patients (66.7 %) have ECOG Performance Status 0-1, whereas 25 patients (32.1%) have performance status > 1. Fifty-eight patients (74%) had dose reduction. No patient achieved objective response, 15 patients (19%) achieved stable disease and 56 patients (72%) had progressive disease. With a median follow up of 6.5 months the median progression free survival was 2.8 months (95% CI 2.5-3.3) and overall survival was 8.0 months, (95% CI 6.2-9.7). Performance status of > 1 and absence of dose reduction had statistically significant impact on progression free survival (p = 0.0002 and 0.0012 respectively).


Regorafenib in clinical practice has equal efficacy to reported data from pivotal registration trials. Our data suggest that performance status and dose reduction are important prognostic factors in patients treated with regorafenib, suggesting careful patients’ selection. Predictive markers are important for such treatment with modest benefit, and significant toxicity and cost.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Shouki Bazarbashi, MBBS.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.